MartIn-Fontecha Alfonso, Sebastiani Silvia, Höpken Uta E, Uguccioni Mariagrazia, Lipp Martin, Lanzavecchia Antonio, Sallusto Federica
Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland.
J Exp Med. 2003 Aug 18;198(4):615-21. doi: 10.1084/jem.20030448.
Antigen-pulsed dendritic cells (DCs) are used as natural adjuvants for vaccination, but the factors that influence the efficacy of this treatment are poorly understood. We investigated the parameters that affect the migration of subcutaneously injected mouse-mature DCs to the draining lymph node. We found that the efficiency of DC migration varied with the number of injected DCs and that CCR7+/+ DCs migrating to the draining lymph node, but not CCR7-/- DCs that failed to do so, efficiently induced a rapid increase in lymph node cellularity, which was observed before the onset of T cell proliferation. We also report that DC migration could be increased up to 10-fold by preinjection of inflammatory cytokines that increased the expression of the CCR7 ligand CCL21 in lymphatic endothelial cells. The magnitude and quality of CD4+ T cell response was proportional to the number of antigen-carrying DCs that reached the lymph node and could be boosted up to 40-fold by preinjection of tumor necrosis factor that conditioned the tissue for increased DC migration. These results indicate that DC number and tissue inflammation are critical parameters for DC-based vaccination.
抗原脉冲树突状细胞(DCs)被用作疫苗接种的天然佐剂,但影响这种治疗效果的因素却知之甚少。我们研究了影响皮下注射的小鼠成熟DCs迁移至引流淋巴结的参数。我们发现,DC迁移效率随注射的DC数量而变化,迁移至引流淋巴结的CCR7+/+ DCs能有效诱导淋巴结细胞数量迅速增加,这在T细胞增殖开始之前就能观察到,而CCR7-/- DCs则无法做到这一点。我们还报告称,通过预先注射炎性细胞因子可使DC迁移增加多达10倍,这些炎性细胞因子能增加淋巴管内皮细胞中CCR7配体CCL21的表达。CD4+ T细胞反应的强度和质量与到达淋巴结的携带抗原的DC数量成正比,通过预先注射肿瘤坏死因子可使反应增强多达40倍,肿瘤坏死因子可使组织适应DC迁移增加。这些结果表明DC数量和组织炎症是基于DC的疫苗接种的关键参数。